

## Nuvilex Signs Agreement to Study Development of Cannabis-Based Cancer Treatments



09 MAY 14

SILVER SPRING, Md., May 9, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has signed a Research Agreement with the University of Northern Colorado to perform initial studies in the development of cancer treatments that combine the proprietary live-cell encapsulation technology known as Cell-in-a-Box(R) with constituents of Cannabis known as cannabinoids. Richard M. Hyslop, Ph.D., Professor of Chemistry and Biochemistry at the University of Northern Colorado and member of the Scientific Advisory Board at Medical Marijuana Sciences, a wholly owned subsidiary of PharmaCyte Biotech, will lead the efforts.

“Dr. Hyslop and his team at the University of Northern Colorado will seek to establish a solid foundation for future preclinical studies and clinical trials that will be needed as Medical Marijuana Sciences develops treatments for serious and deadly diseases such as brain and pancreatic cancers,” said Kenneth L. Waggoner, CEO and president of PharmaCyte Biotech. “The goal is to develop a Cell-in-a-Box(R) /cannabinoid combination that has anticancer effects coupled with low toxicity similar in concept to PharmaCyte Biotech’s pancreatic cancer treatment currently being prepared for Phase 2b clinical trials that uses the Cell-in-a-Box(R) technology with low doses of the chemotherapeutic drug ifosfamide.”

The initial studies to be performed by Dr. Hyslop will be to develop methods for the identification, separation and quantification of constituents (prodrugs) of Cannabis that may be used in combination with PharmaCyte Biotech’s Cell-in-a-Box(R) technology. In addition, studies will be undertaken to identify the appropriate cell type that can convert the selected cannabinoid prodrugs from their naturally-occurring forms into substances that are capable of killing cancer cells. Once identified, the selected cells will be encapsulated using PharmaCyte Biotech’s Cell-in-a-Box(R) technology. The encapsulated cells and cannabinoid prodrugs identified by these studies will then be combined and used for future studies to evaluate their anticancer effectiveness.

### About PharmaCyte Biotech:

PharmaCyte Biotech (NVLX) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech’s treatment for pancreatic cancer involves the widely used anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. PharmaCyte Biotech is also working towards clinical trials associated with the symptoms of advanced pancreatic cancer and other abdominal cancers. PharmaCyte Biotech’s subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box(R) technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop “green” approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide every year.

### Safe Harbor:

This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, that could cause actual results to differ materially from those set forth in the forward-looking statements include PharmaCyte Biotech’s ability to continue as a going concern, delays in clinical trials or flaws or defects regarding its products, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech and Medical Marijuana Sciences can be found at [www.nuvilex.com](http://www.nuvilex.com) and [www.medicalmarijuanasciences.com](http://www.medicalmarijuanasciences.com). It can also be obtained by contacting Investor Relations.

Contact:

Investor Relations Contacts:  
Marlin Molinaro  
Marmel Communications, LLC

Phone: 702.434.8692  
mmolinarofc@aol.com

Media Contact:

Jules Abraham  
JQA Partners, LLC  
Phone: 917.885.7378  
jabraham@jqapartners.com

Posted in [News](#) Posted by [Kenneth L. Waaggoner](#)

---

## Contact Us

PharmaCyte Biotech Inc.  
23046 Avenida de la Carlota, Suite 600  
Laguna Hills, California 92653  
Office Number: 917.595.2850  
Facsimile Number: 917.595.2851  
Email: [info@PharmaCyte.com](mailto:info@PharmaCyte.com)



## Latest News

PharmaCyte Biotech CEO Visiting GMP Facility  
with Cellular Biology Consultant During Production  
of Pancreatic Cancer Product

[4 days ago](#)

PharmaCyte Biotech Proceeding with GMP  
Production of Pancreatic Cancer Product After  
Successful Changes to Manufacturing Process

[18 days ago](#)

## Subscribe to Our Mailing List

\* indicates required

Email Address

First Name

Last Name

**Email Format**

html

text

**Subscribe**

---

To search type and hit enter...